News Channels

26 Sep 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
26 Sep 2023 Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections
25 Sep 2023 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
25 Sep 2023 Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
23 Sep 2023 Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
22 Sep 2023 Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
22 Sep 2023 Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
22 Sep 2023 Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
22 Sep 2023 SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
22 Sep 2023 Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
22 Sep 2023 Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
22 Sep 2023 Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus
22 Sep 2023 Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
22 Sep 2023 Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
21 Sep 2023 Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
21 Sep 2023 Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011
21 Sep 2023 Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
21 Sep 2023 Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
20 Sep 2023 Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
20 Sep 2023 Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up